J&J today presented final long-term (LTE) data from a Phase 3 study demonstrating the efficacy and safety of Stelara (ustekinumab) over four years of treatment in adult patients with an active, moderate to severe form of ulcerative colitis (UC).
Of all patients who achieved a clinical response with Stelara during induction, 64.9% were in symptomatic remission after 44 weeks of treatment.
At week 200 (i.e. after four years), this proportion of patients was 55.2%, and 96.4% of patients were not receiving corticosteroids, specifies the laboratory.
According to Waqqas Afif, an associate professor in the Center's Division of Experimental Medicine and Division of Gastroenterology.
McGill University Health Center in Montreal (Canada), these results demonstrate that 'Stelara may be an effective long-term treatment option for patients with ulcerative colitis'.